Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Head & Neck 2
NL-OMON39253Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Afatinib with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Sep 2012; status: active, not recruiting.
02
Drugs
afatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON39253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39253.